Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
prospective evaluation of topoisomerase II alpha gene amplification and protein
overexpression as markers predicting the efficacy of epirubicin in the primary treatment of
breast cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Jules Bordet Institute
Collaborators:
Centre Hospitalier du Luxembourg Centre Paul Strauss Clinique Louis Cathy - Baudour - Belgium Clinique Saint Pierre - Ottignies -Belgium Clinique Saint Pierre Ottignies Clinique Ste Elisabeth - Namur - Belgium Feculdade de Medicina da Universidade de Sao Paulo - Brasil Gustave Roussy, Cancer Campus, Grand Paris HIS - Site Etterbeek - Ixelles - Belgium University Hospital of Crete